ClinicalTrials.gg
CompletedNCT03033303Updated Oct 30, 2026Results posted

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

A Phase 2 interventional study of Hu3F8 and GM-CSF in Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 30, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing naxitamab in Neuroblastoma — 9 open to participants now, 12 under way, none of them phase 3. naxitamab · Neuroblastoma.

Enrollment
10th of 17
59 · median 62
Started
2017
with 1 other
Phase 2
11 of 17
7 open now
Registered
4th of 17
by date
Lead sponsor
6 of 17
Memorial Sloan Kettering Cancer Center

Among the 17 studies testing naxitamab in Neuroblastoma, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 2, and was the 4th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

9 of the 17 studies testing naxitamab in Neuroblastoma are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About naxitamab

naxitamab: first FDA approval 2020 (DANYELZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing naxitamab in Neuroblastoma, or all of them as a file.
02

Study summary

The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also cause side effects.

03

Conditions studied

  • Neuroblastoma

Browse trials for

Keywords

  • Hu3F8
  • GM-CSF
  • Isotretinoin
  • 16-1643
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of NB as defined by a) histopathology (confirmed by the MSK Department of Pathology), or b) BM or MIBG-avid lesion(s) plus high urine catecholamine levels.
  • Patients must have high-risk NB (MYCN-amplified stage 2/3/4/4S of any age and MYCN-nonamplified stage 4 in patients greater than 18 months of age).
  • Patients must be in first CR/VGPR
  • Patients must have a negative human anti-hu3F8 antibody (HAHA) titer

Exclusion criteria

Exclusion Criteria:

  • Existing major organ dysfunction, i.e., renal., cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity ≥ grade 3, with the exception of hearing loss and hematologic toxicity.
  • Active life-threatening infection.
  • Inability to comply with protocol requirements
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Hu3F8/GM-CSF Plus Isotretinoin

    In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.

    Biological: Hu3F8 · Drug: GM-CSF · Drug: Isotretinoin

Interventions

06

What researchers measure

Primary outcomes

  1. Relapse-free Survival (RFS)

    Patients are considered a response failure under this protocol if progressive disease is evident before two years. Deaths from toxicity attributable to protocol treatment will be counted as events. Patients who withdraw or are lost to followup before two years will be considered as progressions.

    Time frame: 5 years

07

Results

Posted Oct 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneHu3F8/GM-CSF Plus Isotretinoin
Started59
Completed59
Not completed0

Outcome measures

PrimaryRelapse-free Survival (RFS)

Patients are considered a response failure under this protocol if progressive disease is evident before two years. Deaths from toxicity attributable to protocol treatment will be counted as events. Patients who withdraw or are lost to followup before two years will be considered as progressions.

Time frame:
5 years
Reported as:
Median · months
Relapse-free Survival (RFS)
monthsHu3F8/GM-CSF Plus Isotretinoin
Relapse-free Survival (RFS)10.2 (2.3 to 51.0)

Adverse events

Collected over 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hu3F8/GM-CSF Plus Isotretinoin10/59 (16.9%)6/59 (10.2%)59/59 (100%)
Most frequent serious events
Most frequent serious events
EventHu3F8/GM-CSF Plus Isotretinoin
FeverGeneral disorders2/59
Infections and Infestations - Other, specifyInfections and infestations2/59
Sinus tachycardiaCardiac disorders2/59
DehydrationMetabolism and nutrition disorders1/59
Duodenal obstructionGastrointestinal disorders1/59
HypertensionVascular disorders1/59
HyponatremiaMetabolism and nutrition disorders1/59
HypotensionVascular disorders1/59
VomitingGastrointestinal disorders1/59
Most frequent other events
Showing 10 of 17
Most frequent other events
EventHu3F8/GM-CSF Plus Isotretinoin
Lymphocyte count decreasedInvestigations33/59
White blood cell decreasedInvestigations31/59
Platelet count decreasedBlood and lymphatic system disorders28/59
Neutrophil count decreasedInvestigations21/59
Alanine aminotransferase increasedInvestigations19/59
PainGeneral disorders9/59
HypotensionVascular disorders7/59
HyponatremiaMetabolism and nutrition disorders6/59
Aspartate aminotransferase increasedInvestigations4/59
BronchospasmRespiratory, thoracic and mediastinal disorders4/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)Hu3F8/GM-CSF Plus Isotretinoin
Median3.5 (0.46 to 17.8)
Sex: Female, Male
Sex: Female, Male(Participants)Hu3F8/GM-CSF Plus Isotretinoin
Female27
Male32
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Hu3F8/GM-CSF Plus Isotretinoin
Hispanic or Latino2
Not Hispanic or Latino56
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Hu3F8/GM-CSF Plus Isotretinoin
American Indian or Alaska Native0
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American4
White42
More than one race0
Unknown or Not Reported8
Region of Enrollment
Region of Enrollment(Participants)Hu3F8/GM-CSF Plus Isotretinoin
United States59
08

Study locations

1 site
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
09

References and documents

Publications

  • Kushner BH, Modak S, Mauguen A, Basu EM, Kramer K, Roberts SS, Cheung IY, Cheung NV. A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission. Clin Cancer Res. 2025 May 15;31(10):1877-1884. doi: 10.1158/1078-0432.CCR-24-3427. PubMed 40067131 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2025, 104 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's 104 months is above that.

Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2017
First posted
Jan 26, 2017
StartActual
Jan 23, 2017
Primary completionActual
Sep 29, 2025
CompletionActual
Sep 29, 2025
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedrelapseRelapse-free survivalSurvival (RFS)Time frame: 2 years → 5 years
Oct 30, 2026
Documents
Show all 1 update
  1. Oct 30, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedrelapseRelapse-free survivalSurvival (RFS)Time frame: 2 years → 5 years
    + 3 other changes: oversight details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03033303
Collaborators
Y-mAbs Therapeutics
Responsible party
Sponsor
First posted
Jan 26, 2017
Start date
Jan 23, 2017
Primary completion
Sep 29, 2025
Completion
Sep 29, 2025
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Brian H. Kushner, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naxitamab · Granulocyte-Macrophage Colony-Stimulating Factor

Start the discussion